Site References

  1. Klauser AG, Schindlebeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet . 1990;335:205-208.
  2. Jacob P, Kahrilas PJ, Vanagunas A. Peristaltic dysfunction associated with non-obstructive dysphagia in reflux disease. Dig Dis Sci. 1990;35(8):939-942.
  3. Helm JF, Dodds WJ, Hogan WJ. Salivary Response to Esophageal Acid in Normal Subjects and Patients with Reflux Esophagitis. Gastroenterology. 1987;93(6):1393-1397.
  4. Richter JE. Extraesophageal presentations of gastroesophageal reflux disease: an overview. Am J Gastroenterol . 2000;95(8 suppl):S1-S3.
  5. Richter JE. Gastroesophageal Reflux Disease. In: Yamada T, Alpers DH, Kaplowitz N, et al., eds. Textbook of Gastroenterology . 2003; Lippincott Williams & Wilkins: pp.
  6. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: The Genval Workshop Report. Gut. 1999;44 (Suppl 2): S1-S16.
  7. American Gastroenterological Association. The Burden of Gastrointestinal Diseases. American Gastroenterological Association. Bethesda, MD. 2001.
  8. DeVault KR, Castell DO. Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease. Am J Gastroenterol .1999;94 (6):1434-1442.
  9. Ward EM, DeVault KR, Bouras EP, et al. Successful oesophageal pH monitoring with a catheter-free system. Aliment Pharmacol Ther. 2004;19(4):449-454.
  10. Maton PN. Profile and assessment of GERD pharmacotherapy. Cleve Clin J Med. 2003;70(suppl 5):S51-S70.
  11. Hameeteman W, van de Boomgaard DM, Dekker W, et al. Sucralfate versus cimetidine in reflux esophagitis: single-blind multicenter study. J Clin Gastroenterol. 1987;9(4):390-394.
  12. Simon B, Ravelli G-P, Goffin H. Sucralfate gel versus placebo in patient with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1996;10(3):441-446.
  13. Lambert JR, Korman MG, Nicholson L, et al. In-vivo anti-reflux and raft properties of alginates. Aliment Pharmacol Ther. 1990;4(6):615-622.
  14. Ramirez B, Richter J. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease.Aliment Pharmacol Ther. 1993;7(1):5-20.
  15. Smith JL, Opekun AR, Larkai E, et al. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology. 1989;96(3):683-689
  16. Stein HJ, Barlow AP, DeMeester TR, et al. Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann Surg. 1992;216(1):35-43.
  17. Kahrilas PJ. Gastroesophageal reflux disease. JAMA. 1996;276:983-988.
  18. Lipsy RJ, Fennerty B, Fagan TC. Clinical review of histamine2 receptor antagonists. Arch Intern Med. 1990;150(4):745-751.
  19. Howden CW, Henning JM, Huang B, et al. Management of heartburn in a large, randomized, community-based study; comparison of four therapeutic strategies. Am J Gastroenterol. 2001;96(6):1704-1710.
  20. Hatlebakk JG, Berstad A Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis. Scand J Gastroenterol. 1996;31:954-958.
  21. Frislid K, Berstad A. Prolonged influence of a meal on the effect of ranitidine.Scand J Gastroenterol. 1984;19:429-432.
  22. Klinkenberg-Knol E, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease. Gastroenterology. 2000;118:661-669.
  23. Bardhan KD, Morris P, Thompson M, et al. Omeprazole in the treatment of erosive esophagitis refractory to high dose of cimetidine and ranitidine. Gut. 1990. 31(7):745-749.
  24. Huang JQ, Hunt RH. Meta-analysis of comparative trials for healing erosive esophagitis (EE) with proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs). Gastroenterology. 1998;114(4):A154 (abstract G0633).
  25. Richter JE, Campbell DR, Kahrilas PJ et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 2000;160:1803-1809.
  26. Robinson M, Sahba B, Avner D et al. A comparison of lansoprazole and ranitidine in the treatment of erosive esophagitis. Aliment Pharmacol Ther. 1995;9:25-31.
  27. Oberg S, Clark GW, DeMeester TR. Barrett’s esophagus. Update of pathophysiology and management. Hepatogastroenterology. 1998;45(23):1348-1356.
  28. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion.
    1992;51(suppl 1):59-67.
  29. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996;91(9):1749-1757.
  30. Dekkers CP, Beker JA, Thjodleifsson B, et al. Double-blind comparison [correction of Double-blind, placebo controlled comparison] of rabeprazole 20 mg vs.omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1999;13(1):49-57.
  31. Mossner J, Holscher AH, Herz R, et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis; a multicentre trial. Aliment Pharmacol Ther. 1995;9(3):321-326.
  32. Caro JJ, Salas M, Ward A. Healing and Relapse Rates in Gastroesophageal Reflux Disease Treated with the Newer Proton-Pump Inhibitors Lansoprazole, Rabeprazole, and Pantoprazole Compared with Omeprazole, Ranitidine, and Placebo: Evidence from Randomized Clinical Trials. Clin Ther. 2001;23(7):998-1017.
  33. Vigneri S, Termini R, Leandro G, et al.: A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106-1110.
  34. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1994;89(7):989-991.
  35. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996;111:1192-1199.
  36. Marshall REK, Anggiansah A, Manifold DK, et al. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's esophagus. Gut. 1998;43(5):603-606.
  37. Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med. 1997;102(1):78-88.
  38. Goeree R, O’Brien B, Hunt R, et al. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics. 1999;16(6):679-697.
  39. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effective analysis. Am J Gastroenterol. 1997;92(12):2179-2187.
  40. Ladas SD, Tassios PS, Raptis SA. Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring. Am J Gastroenterol. 2000;95(2):374-380.
  41. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121(5):1095-1100.
  42. Katz PO, Anderson C, Khoury R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998;12(12):1231-1234.
  43. Paoletti V, Karvois D, Greski-Rose P, et al. Lansoprazole is superior to omeprazole in increasing both 24-hour and nighttime intragastric pH in "omeprazole failure" GERD patients. Am J Gastroenterol. 1997;92:1621(Abstract).
  44. DeVault KR, Castell DO. Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2005 (100):190-200.
  45. Bell NJV, Burget DW, Howden CW, et al. Healing of gastro-esophageal reflux disease: regression analysis of the role of gastric acid suppression [abstract]. Am J Gastroenterol. 1992;87(9):1253 Abs 46. (Data on file)
  46. Schindlbeck NE, Ippisch H, Klauser AG, et al. Which pH threshold is best in esophageal pH monitoring? Am J Gastroenterol. 1991;86:1138-1141. (Data on file)
  47. Schindlbeck NE, Heinrich C, Konig A, et al. Optimal thresholds, sensitivity, and specificity of long-term pH metry for the detection of gastroesophageal reflux disease. Gastroenterology. 1987;93:85-90. (Data on file)

The information contained in this site is for educational purposes only. It is not intended to recommend any particular treatment plan. It is important that individuals seek and rely on the advice of health care professionals regarding individual medical conditions.